Heterocyclic Compounds

Matches 451 - 500 out of 31,089	< 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 >

Document	Document Title
WO/2023/175185A1	2,4-DIOXO-1,4-DIHYDROQUINAZOLINE DERIVATIVES AS PARG INHIBITORS FOR THE TREATMENT OF CANCER The present invention relates to a compound of formula (I) or an enantiomer, diastereoisomer, tautomer, pharmaceutically acceptable solvate, pharmaceutically acceptable crystal form or a pharmaceutically acceptable salt thereof. The pres...
WO/2023/174406A1	NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to a nitrogen-containing heterocyclic derivative EGFR inhibitor, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by general formula (I)...
WO/2023/177568A1	CANNABINOID RECEPTOR MODULATING COMPOUNDS The application relates to compounds of the general Formula (I) which act as cannabinoid receptor modulators useful for the treatment of complications arising from metabolic, inflammatory and fibrotic disorders.
WO/2023/170025A1	AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are amido cyclopropyl derivatives, methods of preparing such compo...
WO/2023/169453A1	HETEROAROMATIC RING-CONTAINING ALKYNYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to a heteroaromatic ring-containing alkynyl compound, and a preparation method therefor and the use thereof. The heteroaromatic ring-containing alkynyl compound is a compound represented by a formula (I), or...
WO/2023/171788A1	PHOTOELECTRIC CONVERSION ELEMENT, IMAGING ELEMENT, PHOTOSENSOR, AND COMPOUND The present invention addresses the problem of providing: a photoelectric conversion element which is excellent in production applicability and also excellent in photoelectric conversion efficiency; an imaging element; a photosensor; and...
WO/2023/168686A1	SUBSTITUTED CYCLOPENTANES AS CDK2 INHIBITORS The present disclosure provides a compound represented by structural formula (I) : or a pharmaceutically acceptable salt, or a stereoisomer thereof and their use in, e.g. treating a disease or disorder associated with CDK2. This disclosu...
WO/2023/172957A1	THAIZOLE-PYRIMDIINE CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS The disclosure is directed to compounds of Formula (I), pharmaceutical compositions comprising compounds of Formula (I), as well as methods of their use and preparation, are also described.
WO/2023/171920A1	CARBAZOLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME Provided is a high-refractive-index carbazole derivative that effectively absorbs a high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contribute...
WO/2023/173057A1	MEK INHIBITORS AND USES THEREOF The present disclosure provides MEK inhibitors, compositions thereof, and methods of using the same.
WO/2023/171781A1	HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer.　The present inventors have examined compounds useful as an active ingredient of a pharmaceutical composition for treat...
WO/2023/169481A1	TETRAHYDROISOQUINOLINE DERIVATIVE AS PAN-KRAS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF The present invention provides a tetrahydroisoquinoline derivative as a pan-KRAS inhibitor. Specifically, the present invention provides a tetrahydroisoquinoline derivative having a structural formula as shown in general formula (I) and ...
WO/2023/171665A1	PIPERIDINONE DERIVATIVE OR SALT THEREOF, HARMFUL ORGANISM CONTROL AGENT CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME In the production of crops in agriculture, horticulture, etc., due to factors such as damages caused by harmful bugs and the like still being significant and the emergence of harmful bugs resistant to existing drugs, there has been a dem...
WO/2023/170024A1	CAMK2 MODULATORS AND THEIR USE IN MEDICINE The present disclosure relates to compounds which bind Ca2+/calmodulin dependent protein kinase II. It also relates to such compounds for use in the treatment of CNS disorders with sleep disturbances and acute brain injury.
WO/2023/165373A1	MICROMOLECULAR PCSK9 PROTEIN DEGRADATION AGENT, PREPARATION METHOD THEREFOR, AND USE THEREOF Provided are a micromolecular PCSK9 protein degradation agent and a preparation method therefor. The micromolecular PCSK9 inhibitor is a tetrahydroisoquinoline compound having a chemical structure represented by formula (I), or a pharmac...
WO/2023/166039A1	INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR Lasß The present invention relates to compounds of formula (I) and the use thereof as inhibitors of P. aeruginosa virulence factor LasB. These compounds are useful in the treatment of bacterial infections, especially caused by P. aeruginosa.
WO/2023/165551A1	SIX-MEMBERED AROMATIC RING-PYRROLIDONE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF The present application relates to a six-membered aromatic ring-pyrrolidone derivative, and a pharmaceutical composition thereof and the use thereof. The six-membered aromatic ring-pyrrolidone derivative has the structure as shown in for...
WO/2023/165957A1	SUBSTITUTED 1,2,4-THIADIAZOLYL PICOLINAMIDES, SALTS OR N-OXIDES THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES The present invention relates to substituted 1,2,4-thiadiazolyl picolinamide of the general formula (I) or salts thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, and to their ...
WO/2023/165591A1	COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS The present invention disclose novel compounds; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease media...
WO/2023/165943A1	3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS The invention relates to novel compounds having the general formula (I), wherein R1, R10, Rx, Ry, Y, m, and n are as described herein, composition including the compounds and methods of using the compounds.
WO/2023/165958A1	SUBSTITUTED 1,2,4-THIADIAZOLYL ISONICOTINAMIDES, SALTS OR N-OXIDES THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES Substituted 1,2,4-thiadiazolyl isonicotinamide, salts thereof and their use as herbicidally active substances The present invention relates to substituted 1,2,4-thiadiazolyl isonicotinamide of the general formula (I) or salts thereof, wh...
WO/2023/165571A1	COMPOUND CONTAINING FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Disclosed in the present invention are a compound containing a five-membered heteroaromatic ring structure, and a pharmaceutical composition and the use thereof. Provided in the present invention are a compound containing a five-membered...
WO/2023/166153A1	NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA There is provided a compound according to formula (I) or a pharmaceutically acceptable salt or prodrug thereof.
WO/2023/164050A1	COMPOUNDS AS GLP-1R AGONISTS The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, o...
WO/2023/163033A1	NOVEL COMPOUND, α-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF Provided is a compound that has high binding selectivity to α-synuclein aggregates.　The present invention relates to a compound represented by formula (I), (II) or (III), a pharmaceutically acceptable salt thereof, or a solvate of the...
WO/2023/164179A1	BENZOTHIA(DIA)ZEPINE COMPOUNDS FOR TREATMENT OF HBV AND HDV The present disclosure provides, in part, benzothia(dia) zepine compounds of formula II and pharmaceutical compositions thereof, and methods of treating Hepatitis B (HBV) and Hepatitis D (HDV) infections.
WO/2023/164183A1	BENZOTHIA(DIA)ZEPINE COMPOUNDS FOR TREATMENT OF HBV AND HDV The present disclosure provides, in part, benzothia(dia)zepine compounds, and pharmaceutical compositions thereof, and methods of treating Hepatitis B (HBV) and Hepatitis D (HDV) infections.
WO/2023/161316A1	ZWITTERIONIC ANTIBACTERIAL COMPOUNDS The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A, X, R1-R9, R12 and R13 are as described herein (I). Further provided are pharmaceutical ...
WO/2023/160634A1	BENZOTHIAZOLE COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed in the present invention are benzothiazole compounds as well as a preparation method therefor and the use thereof. The compounds have a great inhibition effect on SARS-CoV-2 and can be used for resisting the novel coronavirus. (I)
WO/2023/160638A1	RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF This disclosure provides compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e. g., including those mediated by receptor-interacting protein ...
WO/2023/164250A1	SEC61 INHIBITORS AND USE THEREOF Provided herein are secretion inhibitors, such as inhibitors of Sec61 having a structure of formula (I): methods for their preparation, related pharmaceutical compositions, and methods for using the same.
WO/2023/155710A1	IKZF2 DEGRADATION AGENT, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND USE THEREOF The present invention belongs to the field of medicinal chemistry, and relates to an IKZF2 degradation agent, a pharmaceutical composition comprising same and use thereof. Specifically, the IKZF2 degradation agent has a structure represe...
WO/2023/159155A1	INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) AND USES THEREOF Disclosed herein are compounds of Formulae 1A, 1B, 1C and 1D, (1A), (1B), (1C) and (1D) and methods of making and methods of using the same.
WO/2023/156863A1	PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF Provided is an inhibitor of AXL, Mer, and/or c-Met of Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I), in which R1, R2, R3, G, and Q are described herein. Further provided is a method of treating or preventing an A...
WO/2023/155927A1	INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF The present disclosure provides an inhibitor, represented by formula I, of interaction between YAP/TAZ and TEAD, preparation thereof, a pharmaceutical composition thereof and use thereof. The compound provided in the present disclosure c...
WO/2023/155454A1	CARBONIC ANHYDRASE IX-TARGETING RADIOACTIVE DIAGNOSTIC AND THERAPEUTIC MEDICAMENT AND METHOD FOR PREPARING SAME The present invention relates to a carbonic anhydrase IX-targeting radioactive diagnostic and therapeutic medicament and a method for preparing same, and in particular, relates to a compound represented by formula (I), or a pharmaceutica...
WO/2023/158795A1	INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
WO/2023/151640A1	HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH Provided herein are compounds having the structure (I), wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of an immune cell.
WO/2023/152666A1	3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS The present invention provides 3-substituted pyridazine compound of formula (I), which are therapeutically useful as SMARCA2 and/or SMARCA4 degraders. These compounds are useful in the treatment and/or prevention of diseases or disorders...
WO/2023/151697A1	METTL3 INHIBITOR AND COMPOSITION, AND APPLICATION OF SAME IN MEDICINE The present invention relates to a compound represented by general formula (I) or a stereoisomer, a tautomer, a deuterated substance, a solvate, a prodrug, a metabolite and a pharmaceutically acceptable salt or eutectic crystal thereof, ...
WO/2023/154913A1	INHIBITORS OF PARG The present invention relates to sulfonamides and related compounds which are inhibitors of PARG and are useful in the treatment of cancer.
WO/2022/178428A9	TARGETED BIFUNCTIONAL DEGRADERS AND METHODS USING SAME The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of an extracellular or cell surface protein. In certain embodiments, the extracellular protein mediates a disease a...
WO/2023/152773A1	SOLID FORMS OF MOMELOTINIB SALTS AND IMPROVED PROCESSES FOR THE PREPARATION OF MOMELOTINIB The present invention relates to the Amorphous Solid Dispersions (ASDs) of Momelotinib di-hydrochloride and processes for preparation thereof. Compared to a crystalline form, a stable amorphous form of Momelotinib di-hydrochloride enhanc...
WO/2023/153748A1	SOS1 INHIBITOR AND DERIVATIVE THEREOF The present invention relates to an SOS1 inhibitor and a derivative thereof. A compound, or a pharmaceutically acceptable salt, hydrate, solvate, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof of the present in...
WO/2023/154519A1	INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Provided are compounds of the Formula (I); or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
WO/2023/150523A1	PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND USES THEREOF Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), ...
WO/2023/150535A1	PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND USES THEREOF Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), ...
WO/2023/150526A1	COMPETITIVE AND NONCOMPETITIVE OCTAHYDROCYCLOPENTA[C]PYRROLE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 Arylsulfonamides of 5-substituted octahydrocyclopenta[c]pyrroles, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatr...
WO/2023/148501A1	HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS The present invention relates to compounds of formula (I) that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to p...
WO/2023/150525A1	COMPETITIVE AND NONCOMPETITIVE PIPERIDINE SULFONYL INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 Arylsulfonamides of 4-substituted-piperidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatric disorders such a...

Matches 451 - 500 out of 31,089	< 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 >